This is a working overview of Thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
=== Nixon's resignation === On 9 August 1974, Nixon resigned in the wake of the Watergate scandal. Vice President Gerald Ford assumed the presidency. Ford kept Kissinger on as both National Security Advisor and Secretary of State. Around the same time, the South Vietnamese economy, under the weight of inflation caused by the Arab oil shock and rampant corruption, collapsed. By the summer of 1974, the U.S. embassy reported that morale in the ARVN had fallen to dangerously low levels and it was uncertain how much longer South Vietnam would last. The South Vietnamese regime had lost popular support, with widespread protests against corruption breaking out; protestors accused Thiệu and his family of corruption. In August 1974, Congress passed a bill limiting American aid to South Vietnam to $700 million annually. By November 1974, fearing the worst for South Vietnam as the ARVN continued to retreat, Kissinger, during the Vladivostok Summit, lobbied Brezhnev to end Soviet military aid to North Vietnam. The same month, during a visit to Beijing, he lobbied Mao and Zhou to do the same.
acidic type I hair keratin type I hair keratin 1, KRT31 type I hair keratin 2, KRT32 type I hair keratin 3A, KRT33A type I hair keratin 3B, KRT33B type I hair keratin 4, KRT34 type I hair keratin 5, KRT35 type I hair keratin 6, KRT36 type I hair keratin 7, KRT37 type I hair keratin 8, KRT38 basic type II hair keratin type II hair keratin 1, KRT81 type II hair keratin 2, KRT82 type II hair keratin 3, KRT83 type II hair keratin 4, KRT84 type II hair keratin 5, KRT85 type II hair keratin 6, KRT86
Both sides have made conflicting claims about the position of chief ministers from these states. A Wall Street Journal article reports that in Uttar Pradesh, Uma Bharti, a senior leader of the opposition Bharatiya Janata Party (BJP), threatened to "set fire to the first Wal-Mart store whenever it opens;" with her colleague Sushma Swaraj busy tweeting up a storm of misinformation about how Wal-Mart allegedly ruined the U.S. economy. On 1 December 2011, an India-wide "bandh" (close all business in protest) was called by political parties opposing the retail reform. While many organisations responded, the reach of the protest was mixed. The Times of India, a national newspaper of India, claimed people appeared divided over the bandh call and internal rivalry among trade associations led to a mixed response, leaving many stores open day-long and others opening for business as usual in the second half of the day. Even Purti Group, a network of stores owned and operated by Nitin Gadkari were open for business, ignoring the call for bandh. Gadkari is the president of BJP, the key party currently organising opposition to retail reform. The Hindu, another widely circulated newspaper in India, claimed the opposition's call for a nationwide shutdown on 1 December 2011, in protest of retail reform received a mixed response. Some states had strong support, while most did not. Even in states where opposition political parties are in power, many ignored the call for the shutdown. In Gujarat, Bihar, Delhi, Andhra Pradesh, Haryana, Punjab and Assam the call evoked a partial response.
In September 1936, Fry's released an aerated Crunchie bar made entirely of chocolate. They justified this move as not breaching the patent, saying it was not a block but a bar. As Aero sales began to dip, Rowntree's brought out variants, selling the first aerated chocolates with fruit and nut inclusions. After Fry's launched a second aerated chocolate in August 1937 called Ripple, Rowntree's had to decide whether they wanted to try to enforce their patent. By this time, Nestlé and Fry's had joined Cadbury in having expressed a willingness to challenge the patent in the courts despite it being officially approved by the patent office. On legal advice that there was a 50% likelihood of success in a court challenge, and the threat of court proceedings causing bad publicity, Rowntree's entered negotiations with other chocolate makers to discuss licensing aerated chocolate. Rival companies were dominant in the proceedings dialogues, and Rowntree's ultimately agreed to licence aerated chocolate from June 1938 under the conditions that chocolate makers pay a sum with the release of new aerated chocolate lines and a 0.5% royalty on sales. After this agreement was put in place, Cadbury only released aerated chocolate products in overseas dominions where Aero was not established. Nestlé-produced aerated chocolates included a chocolate called Bubblo, made in the UK for export to New Zealand under a New Zealand patent. Aerated chocolate was already being sold in some overseas markets, by 1936 for instance, Aero was being successfully exported to Australia.
Sources: en.wikipedia.org
Surface-supplied diving equipment (SSDE) is the equipment required for surface-supplied diving. The essential aspect of surface-supplied diving is that breathing gas is supplied from the surface, either from a specialised diving compressor, high-pressure gas storage cylinders, or both. In commercial and military surface-supplied diving, a backup source of surface-supplied breathing gas should always be present in case the primary supply fails. The diver may also wear a bailout cylinder (emergency gas supply) which can provide self-contained breathing gas in an emergency. Thus, the surface-supplied diver is less likely to have an "out-of-air" emergency than a scuba diver using a single gas supply, as there are normally two alternative breathing gas sources available. Surface-supplied diving equipment usually includes communication capability with the surface, which improves the safety and efficiency of the working diver. The equipment needed for surface supplied diving can be broadly grouped as diving and support equipment, but the distinction is not always clear. Diving support equipment is equipment used to facilitate a diving operation. It is either not taken into the water during the dive, such as the gas panel and compressor, or is not integral to the actual diving, being there to make the dive easier or safer, such as a surface decompression chamber. Some equipment, like a diving stage, is not easily categorised as diving or support equipment, and may be considered as either.
== Research == Bunch was a postdoctoral researcher at the University of Sheffield, where she was awarded an Enterprise Fellowship to commercialise imaging using mass spectrometry. She joined the University of Birmingham, leading a large multi-disciplinary group using MALDI Mass spectrometry. She remains an honorary senior research fellow at the University of Birmingham. She also holds a chair in Biomolecular Mass Spectrometry at Imperial College London. She joined the National Physical Laboratory in 2013, where she became responsible for research in MALDI metrology. In 2017 Bunch was funded by Cancer Research UK's Grand Challenge to map tumours at a molecular and cellular level. She came up with the idea when listening to a BBC Radio 4 program about the Cancer Research UK Grand Challenges. The investment was worth £16 million, and uses mass spectrometry imaging techniques to study breast, bowel and pancreatic tumours in "unprecedented detail. She spoke about the project at the Hay Festival and presented their project at the Royal Society Summer Exhibition. She is part of a COST (European Cooperation in Science and Technology) Action on mass spectrometry imaging.
Often, only between 10 and 15 mites are involved in an infection. Scabies most often spreads during a relatively long period of direct skin contact with an infected person (at least 10 minutes) such as that which may occur during sexual activity or living together. Spread of the disease may occur even if the person has not developed symptoms yet. Crowded living conditions, such as those found in child-care facilities, group homes, and prisons, increase the risk of spread. Areas with a lack of access to water also have higher disease rates. Crusted scabies is a more severe form of the disease, not essentially different but an infestation by huge numbers of mites that typically only affects those with a poor immune system; the number of mites also makes them much more contagious. In these cases, the spread of infection may occur during brief contact or by contaminated objects. The mite is tiny and at the limit of detection with the human eye. It is not readily obvious; factors that aid in detection are good lighting, magnification, and knowing what to look for. Diagnosis is based either on detecting the mite (confirmed scabies), detecting typical lesions in a typical distribution with typical histological features (clinical scabies), or detecting atypical lesions or atypical distribution of lesions with only some histological features present (suspected scabies). Several medications are available to treat those infected, including oral and topical ivermectin, permethrin, crotamiton, and lindane creams.
Sources: en.wikipedia.org
== Further reading == Milosevic, V., Edelmann, R.J., Fosse, J.H., Östman, A., Akslen, L.A. (2022). Molecular Phenotypes of Endothelial Cells in Malignant Tumors. In: Akslen, L.A., Watnick, R.S. (eds) Biomarkers of the Tumor Microenvironment. Springer, Cham. https://doi.org/10.1007/978-3-030-98950-7_3
== Biological functions == (Z)-9-Tricosene is a sex pheromone produced by female house flies (Musca domestica) to attract males. In bees, it is one of the communication pheromones released during the waggle dance.
=== LFA-1 and LFA-3–based therapeutics for autoimmune disease === Although Springer made the first antibodies to LFA-1 and LFA-3, he did not patent them. An antibody isolated by Hildreth and McMichael was licensed to Genentech, which was humanized and approved by the FDA in 2003 for moderate to severe psoriasis as Raptiva. Its generic name efalizumab simulate the letters F and L in LFA-1. Springer and lab member Mike Dustin collaborated with Barbara Wallner at Biogen to clone the cDNA for LFA-3. The LFA-3 ectodomain, which contains one immunoglobulin-like domain, was fused to the Fc domain of IgG to create Amevive. Amevive was approved for moderate to severe psoriasis in 2003. Its generic name, alefacept, is a homophone of LFA plus "cept" from receptor. Royalties paid by Biogen to Dana Farber Cancer Institute were equally shared by Dustin and Springer.
"Half and half" or "Half-and-half" is a mixture of milk and cream, which is often used in coffee and with breakfast cereals. In the United States, half and half is a common liquid product produced by dairy companies in premixed form. It was invented by William A. Boutwell of Boutwell Dairy in Lake Worth Beach, Florida, which distributed the blend regionally between 1927 and 1956. In the United States, half-and-half must contain between 10.5 and 18 percent milkfat. It is pasteurized or ultra-pasteurized, and may be homogenized. The following optional ingredients may also be used:
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.